Jan 31, 2007 by Brian LawlerFDA Says Hurray for More Drug SafetyThe FDA outlines its proposal to increase drug safety.
Jan 31, 2007 by Brian LawlerMylan on the Generic AttackTwo new drug approvals for Mylan come in the midst of a changing regulatory environment.
Jan 30, 2007 by Brian LawlerSchering-Plough Pushes AheadThe drugmaker successfully continues with its multiyear turnaround plan.
Jan 30, 2007 by Brian LawlerIs Bigger Better for Abbott Labs?Abbott continues its transformation into a more focused pharmaceutical powerhouse.
Jan 30, 2007 by Brian LawlerPar Passes the Generic BarPar gets approval to market another generic product, but the company still has to complete the restatement of its past financials.
Jan 30, 2007 by Brian LawlerPfizer Fights a Generic ThreatPfizer attempts to fend off a generic threat in Canada for its top drug.
Jan 30, 2007 by Brian LawlerWyeth's Slow GrowthWyeth releases its 2006 financial results and guides for another year of slow growth.
Jan 29, 2007 by Brian LawlerNo Amplified Growth for AmgenToo rich for my blood. Still, that R&D spending isn't for nothing.
Jan 29, 2007 by Brian LawlerImClone Fights the CompetitionImClone's performance has been all right, but the competition is heating up.
Jan 29, 2007 by Brian LawlerBristol-Myers Blames the Generic AgainThe fourth quarter's financial results are dominated by generic competition.
Jan 29, 2007 by Brian LawlerNo Dicey Results for CubistThe stock price may be down, but Cubist is looking strong.
Jan 29, 2007 by Brian LawlerThe Paris Hilton of Drug StocksYet another rumor about a potential merger for Bristol-Myers.
Jan 25, 2007 by Brian LawlerRenovis Tries to Right ItselfRenovis takes some steps to try and recover after its lead drug fails in clinical testing.
Jan 25, 2007 by Brian LawlerDiscovery Finds Its WayDiscovery updates investors on the timeline to potentially bring its lead product to market.
Jan 25, 2007 by Brian LawlerJohnson & Johnson's Earnings GleeJNJ keeps growing, even if the pharmaceutical segment is a bit sluggish.
Jan 24, 2007 by Brian LawlerNeurocrine in the Green2006 wasn't kind to drug developer Neurocrine Biosciences.
Jan 24, 2007 by Brian Lawler3 Drug Stocks to WatchAdd these to your watch list if you're looking to hit it big.
Jan 23, 2007 by Brian LawlerNo Generic Profit for ReddyDr. Reddy's continues to expand its generics business globally.
Jan 22, 2007 by Brian LawlerThe Feds Eye EndoEndo Pharmaceuticals' sales practices for Lidoderm prompt government scrunity.
